Does the final report and approval of CHECKMATE 227 (ipi/nivo) regimen change your first line recommendations for patients with PDL1 TPS < 1%?  


Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Kaiser Permanente
Thanks for the data. It looks like the median foll...
Medical Oncologist at University of Minnesota Medical School
From the available data it is difficult to know wh...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution